Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 73.17 CNY 1.96% Market Closed
Market Cap: 92.5B CNY
Have any thoughts about
Beijing Wantai Biological Pharmacy Enterprise Co Ltd?
Write Note

Operating Margin
Beijing Wantai Biological Pharmacy Enterprise Co Ltd

-21.9%
Current
29%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-21.9%
=
Operating Profit
-544.9m
/
Revenue
2.5B

Operating Margin Across Competitors

Country CN
Market Cap 92.8B CNY
Operating Margin
-22%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
92.8B CNY
Industry
Biotechnology

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has emerged as a key player in the Chinese biopharmaceutical landscape, combining innovation with a commitment to improving healthcare outcomes. Founded in 1990, the company specializes in the research, development, manufacturing, and sale of a wide range of vaccines, diagnostic reagents, and biologic drugs. As one of the forefront companies in China's biotech sector, Wantai has leveraged its technological expertise to create products that address significant public health needs, such as viral infections and autoimmune diseases. With a robust pipeline and strong government support, the company positions itself as a critical contributor to the nation's healthcare ecosystem while aligning with global trends in biopharmaceutical development. For investors, Wantai represents an attractive opportunity, particularly as the demand for effective vaccines and diagnostics continues to surge worldwide. The company's recent IPO and strategic partnerships have bolstered its financial standing, providing a solid foundation for future growth. With an expanding portfolio that includes COVID-19 vaccines and innovative therapeutics, Wantai is poised to capitalize on the growing emphasis on preventative medicine and public health. Moreover, the company's commitment to quality and extensive research capabilities create a sustainable competitive advantage that could yield promising returns for investors navigating the evolving biotechnology market.

Intrinsic Value
63.19 CNY
Overvaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-21.9%
=
Operating Profit
-544.9m
/
Revenue
2.5B
What is the Operating Margin of Beijing Wantai Biological Pharmacy Enterprise Co Ltd?

Based on Beijing Wantai Biological Pharmacy Enterprise Co Ltd's most recent financial statements, the company has Operating Margin of -21.9%.